Balancing of Patients Treated by Vitamin K Antagonists (VKAS) in General Medicine — VKA  

Thromboembolism Clinical Trial

Official title: Balancing of Patients Treated by Vitamin K Antagonists (VKAS) in General Medicine : Study ok Variables Influencing the Time Paid in the Therapeutic Target

Status Completed

Clinical Trial Summary

Despite the rise in prescriptions for direct oral anticoagulants,Vitamin K antagonists(VKA) remains the most prescribed treatment for treating and preventing long-term thromboembolic events. They remain the most important drugs of iatrogenic accidents despite the means deployed by the health authorities. The balance of the patients under VKA can be appreciated thanks to the time spent in the therapeutic zone or TTR which is correlated with the risk of occurrence of haemorrhagic or thrombotic events.

Clinical Trial Description

Despite the rise in prescriptions for direct oral anticoagulants, Vitamin K antagonists (VKA) remains the most prescribed treatment for treating and preventing long-term thromboembolic events. They remain the most important drugs of iatrogenic accidents despite the means deployed by the health authorities. The balance of the patients under VKA can be appreciated thanks to the time spent in the therapeutic zone or TTR which is correlated with the risk of occurrence of haemorrhagic or thrombotic events.

The management of VKA in France seems hardly comparable to that of the neighboring countries in front of:

• A TTR estimated at 60%.

• Majority management of anticoagulant treatments by general practitioners.

• The weak development of clinics anticoagulants.

• The takeoff of direct oral anticoagulant prescriptions.

• Preponderance of fluindione prescriptions among the various oral anticoagulants.

It therefore seems interesting to study a cohort of French patients under VKA. Through the calculation of the TTR, the investigators will be able to draw a picture of the balance of the anticoagulant treatment and try to identify factors that can influence it. ;

Related Conditions & MeSH terms

• Thromboembolism

• NCT number: NCT03914053
• Study type: Observational
• Source: University Hospital, Montpellier
• Status: Completed
• Start date: July 1, 2017
• Completion date: December 31, 2018